EntreMed, Inc. (NASDAQ: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers, today announced the issuance by the Chinese State Intellectual Property Office of Patent Certificate No. ZL...
EntreMed, Inc. (NASDAQ: ENMD) announced today that its Board of Directors has appointed two new individuals as directors. Joining the Board are James Huang and Y. Alexander Wu, Ph.D.
(Logo: http://photos.prnewswire.com/prnh/20010620/ENMDLOGO...
Below are highlights from Benzinga's daily coverage of small cap securities making big moves:
EntreMed
Shares of EntreMed (NASDAQ: ENMD), the Rockville, MD clinical-stage pharmaceutical company, rose 15% Wednesday on 5 times average...
EntreMed (NASDSQ: ENMD) announced today the initiation of a single-center Phase 2 study entitled "A Phase 2 Study of Oral ENMD-2076 Administered to Patients with Advanced/Metastatic Soft Tissue Sarcoma" at Princess Margaret Hospital where the...
Below are highlights from Benzinga's daily coverage of small cap securities making big moves:
EntreMed
Shares of EntreMed (NASDAQ: ENMD), the Rockville, MD clinical-stage pharmaceutical company, rose 26% Monday on 6 times average...
EntreMed (NASDAQ: ENMD) announced today that EntreMed has submitted a new drug clinical trial application with China's State Food and Drug Administration (SFDA) for its proprietary drug candidate, ENMD-2076, to conduct global clinical trials in...
EntreMed (NASDAQ: ENMD) announced today the initiation of a second site for its Phase 2 study of ENMD-2076 in triple-negative breast cancer (TNBC). Kathy Miller, MD, Associate Professor at the Melvin and Bren Simon Cancer Center at Indiana...
China BAK Battery, Inc. (Nasdaq: CBAK) 72.7% HIGHER; making a strong move back above the key $2 level on tremendous volume today.
EntreMed, Inc. (Nasdaq: ENMD) 29.4% HIGHER; announced the publication of favorable results of a preclinical study in...
Oops! Unable to complete your request. Please refresh your browser.